Public Employees Retirement Association of Colorado Raises Holdings in Charles River Laboratories Intl. Inc (NYSE:CRL)

Public Employees Retirement Association of Colorado lifted its stake in Charles River Laboratories Intl. Inc (NYSE:CRL) by 2,050.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 163,199 shares of the medical research company’s stock after buying an additional 155,609 shares during the quarter. Public Employees Retirement Association of Colorado owned approximately 0.33% of Charles River Laboratories Intl. worth $21,603,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Capital Insight Partners LLC bought a new stake in shares of Charles River Laboratories Intl. in the second quarter valued at about $1,087,000. Retirement Systems of Alabama raised its holdings in shares of Charles River Laboratories Intl. by 0.4% in the second quarter. Retirement Systems of Alabama now owns 146,613 shares of the medical research company’s stock valued at $20,804,000 after acquiring an additional 634 shares in the last quarter. Copper Rock Capital Partners LLC grew its stake in Charles River Laboratories Intl. by 8.4% in the second quarter. Copper Rock Capital Partners LLC now owns 187,521 shares of the medical research company’s stock valued at $26,609,000 after purchasing an additional 14,478 shares during the last quarter. Zions Bancorporation N.A. grew its stake in Charles River Laboratories Intl. by 5.4% in the second quarter. Zions Bancorporation N.A. now owns 2,421 shares of the medical research company’s stock valued at $344,000 after purchasing an additional 124 shares during the last quarter. Finally, New England Research & Management Inc. purchased a new position in Charles River Laboratories Intl. in the second quarter valued at about $990,000. Hedge funds and other institutional investors own 94.31% of the company’s stock.

NYSE CRL traded up $1.53 during trading hours on Monday, reaching $132.04. The stock had a trading volume of 6,198 shares, compared to its average volume of 360,739. The stock has a fifty day moving average of $132.15 and a 200 day moving average of $133.41. The stock has a market cap of $6.39 billion, a P/E ratio of 21.76, a price-to-earnings-growth ratio of 2.00 and a beta of 1.08. Charles River Laboratories Intl. Inc has a 52-week low of $103.00 and a 52-week high of $149.07. The company has a debt-to-equity ratio of 1.47, a quick ratio of 1.38 and a current ratio of 1.59.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $1.69 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.64 by $0.05. The company had revenue of $668.00 million during the quarter, compared to the consensus estimate of $674.08 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. Charles River Laboratories Intl.’s revenue for the quarter was up 14.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.53 earnings per share. On average, equities research analysts forecast that Charles River Laboratories Intl. Inc will post 6.53 EPS for the current year.

Several equities analysts have issued reports on CRL shares. SunTrust Banks lifted their target price on Charles River Laboratories Intl. from $156.00 to $162.00 and gave the company a “buy” rating in a research note on Monday, September 16th. ValuEngine lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday, October 21st. UBS Group cut their target price on Charles River Laboratories Intl. from $147.00 to $145.00 and set a “neutral” rating on the stock in a research note on Thursday. Finally, Credit Suisse Group set a $138.00 target price on Charles River Laboratories Intl. and gave the company a “hold” rating in a research note on Friday, September 13th. Eight equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $150.50.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.